|
CA1327358C
(en)
|
1987-11-17 |
1994-03-01 |
Morio Fujiu |
Fluoro cytidine derivatives
|
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク，インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
|
US6407213B1
(en)
|
1991-06-14 |
2002-06-18 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
|
TW254946B
(fi)
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
|
TW398975B
(en)
|
1994-07-22 |
2000-07-21 |
Lilly Co Eli |
Pharmaceutical composition for inhibiting bone loss
|
|
US5476932A
(en)
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
JP4009681B2
(ja)
|
1995-11-07 |
2007-11-21 |
キリンファーマ株式会社 |
血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
|
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
|
AU763669B2
(en)
|
1998-09-29 |
2003-07-31 |
Wyeth Holdings Corporation |
Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
|
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
|
CA2396079A1
(en)
|
2000-01-07 |
2001-07-19 |
Transform Pharmaceuticals, Inc. |
High-throughput formation, identification, and analysis of diverse solid-forms
|
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
EP1318837B1
(en)
|
2000-08-11 |
2004-10-06 |
Wyeth |
Method of treating estrogen receptor positive carcinoma
|
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
|
CN1309421C
(zh)
|
2001-04-06 |
2007-04-11 |
惠氏公司 |
诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合
|
|
TWI233359B
(en)
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
|
TWI296196B
(en)
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
|
MXPA03010907A
(es)
|
2001-06-01 |
2004-02-17 |
Wyeth Corp |
Combinaciones antineoplasicas.
|
|
ZA200603888B
(en)
|
2001-06-01 |
2007-05-30 |
Wyeth Corp |
Antineoplastic combinations
|
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
|
CA2467573A1
(en)
|
2001-11-27 |
2003-06-19 |
Wyeth Holdings Corporation |
3-cyanoquinolines as inhibitors of egf-r and her2 kinases
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
ATE547708T1
(de)
|
2002-06-05 |
2012-03-15 |
Cedars Sinai Medical Center |
Verfahren zur handhabung der kinasehemmertherapie
|
|
WO2004004644A2
(en)
|
2002-07-05 |
2004-01-15 |
Beth Israel Deaconess Medical Center |
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
|
|
US20040209930A1
(en)
|
2002-10-02 |
2004-10-21 |
Carboni Joan M. |
Synergistic methods and compositions for treating cancer
|
|
CL2004000016A1
(es)
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
|
UA83484C2
(uk)
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
|
US20040258662A1
(en)
|
2003-04-22 |
2004-12-23 |
Wyeth |
Antineoplastic agents
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
DE602004010407T2
(de)
|
2003-07-23 |
2008-10-16 |
Bayer Pharmaceuticals Corp., West Haven |
Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
|
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
|
MXPA06001110A
(es)
|
2003-08-01 |
2006-04-11 |
Wyeth Corp |
Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.
|
|
JP2007502819A
(ja)
|
2003-08-19 |
2007-02-15 |
ワイス・ホールディングズ・コーポレイション |
４−アミノ−３−キノリンカルボニトリルの調製方法
|
|
CA2537978C
(en)
|
2003-09-15 |
2011-08-02 |
Wyeth |
Substituted quinolines as protein tyrosine kinase enzyme inhibitors
|
|
US7399865B2
(en)
*
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
|
EP1756137A4
(en)
|
2003-11-05 |
2007-10-31 |
Univ Texas |
DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
|
|
PE20050928A1
(es)
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
|
AR047988A1
(es)
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
|
BRPI0508286B8
(pt)
|
2004-03-31 |
2021-05-25 |
Dana Farber Cancer Inst Inc |
método para determinar a probabilidade de eficácia de um inibidor da tirosina quinase egfr para tratar câncer, uso de um inibidor da tirosina quinase de egfr, sonda, kit, e, par de iniciadores
|
|
AU2005263972A1
(en)
|
2004-07-23 |
2006-01-26 |
Astrazeneca Ab |
Method of predicting the responsiveness of a tumor to erbB receptor drugs
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
|
BRPI0516592A
(pt)
|
2004-10-13 |
2008-09-23 |
Wyeth Corp |
composto de fórmula
|
|
US20080254497A1
(en)
|
2004-10-15 |
2008-10-16 |
Monogram Biosciences, Inc. |
Response Predictors for Erbb Pathway-Specific Drugs
|
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
WO2006084058A2
(en)
|
2005-02-03 |
2006-08-10 |
The General Hospital Corporation |
Method for treating gefitinib resistant cancer
|
|
WO2006081985A1
(en)
|
2005-02-04 |
2006-08-10 |
F. Hoffmann-La Roche Ag |
Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
|
|
JPWO2006090930A1
(ja)
|
2005-02-28 |
2008-07-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホンアミド化合物の新規併用
|
|
WO2006098978A1
(en)
|
2005-03-09 |
2006-09-21 |
Abbott Laboratories |
Diagnostics method for identifying candidate patients for the treatment with trastuzumab
|
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
|
CN101160129A
(zh)
|
2005-04-14 |
2008-04-09 |
惠氏公司 |
表皮生长因子受体激酶抑制剂在吉非替尼抗性患者中的使用
|
|
WO2006116016A2
(en)
|
2005-04-21 |
2006-11-02 |
The Regents Of The University Of California |
Molecular determinants of egfr kinase inhibitor response in glioblastoma
|
|
TW200716129A
(en)
|
2005-04-28 |
2007-05-01 |
Wyeth Corp |
Micronized tanaproget, compositions, and methods of preparing the same
|
|
US20080193448A1
(en)
|
2005-05-12 |
2008-08-14 |
Pfizer Inc. |
Combinations and Methods of Using an Indolinone Compound
|
|
RU2007143161A
(ru)
|
2005-05-25 |
2009-07-10 |
Вайет (Us) |
Способы синтеза замещенных 3-цианохинов и их продуктов
|
|
RU2007139544A
(ru)
|
2005-05-25 |
2009-06-27 |
Вайет (Us) |
Способ получения 3-цианохинолинов и промежуточные соединения, полученные согласно данному способу
|
|
DE102005053679A1
(de)
|
2005-06-24 |
2006-12-28 |
Bayer Healthcare Ag |
Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
|
|
TW200740427A
(en)
|
2005-07-15 |
2007-11-01 |
Wyeth Corp |
Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
|
|
JP5066446B2
(ja)
|
2005-08-01 |
2012-11-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を予測する方法
|
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
|
WO2007039705A1
(en)
|
2005-10-05 |
2007-04-12 |
Astrazeneca Uk Limited |
Method to predict or monitor the response of a patient to an erbb receptor drug
|
|
WO2007050495A2
(en)
|
2005-10-26 |
2007-05-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
|
TW200803842A
(en)
|
2005-11-04 |
2008-01-16 |
Wyeth Corp |
Antineoplastic combinations of temsirolimus and sunitinib malate
|
|
WO2007056118A1
(en)
|
2005-11-04 |
2007-05-18 |
Wyeth |
Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
|
|
US20090306101A1
(en)
|
2005-11-11 |
2009-12-10 |
Flavio Solca |
Combination treatment of cancer comprising egfr/her2 inhibitors
|
|
WO2007059821A1
(en)
|
2005-11-24 |
2007-05-31 |
Aicuris Gmbh & Co. Kg |
Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
|
|
WO2007075794A2
(en)
|
2005-12-22 |
2007-07-05 |
Wyeth |
Oral formulations comprising tigecycline
|
|
WO2007095038A2
(en)
|
2006-02-09 |
2007-08-23 |
Novartis Ag |
Mutations and polymorphisms of erbb2
|
|
TW200806282A
(en)
|
2006-05-05 |
2008-02-01 |
Wyeth Corp |
Solid dosage formulations
|
|
IL282783B2
(en)
|
2006-05-18 |
2023-09-01 |
Caris Mpi Inc |
A system and method for determining a personalized medical intervention for a disease stage
|
|
TW200808728A
(en)
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
|
CA2655997A1
(en)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Igfbp2 biomarker
|
|
RU2492864C2
(ru)
|
2006-09-18 |
2013-09-20 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способ лечения рака, несущего мутации egfr
|
|
EP2077819A4
(en)
|
2006-09-28 |
2011-05-25 |
Follica Inc |
METHODS, MATERIALS, AND COMPOSITIONS FOR GENERATING NEW CELLULAR FOLLICLES AND PUSHING HAIR
|
|
EP2073823A1
(en)
|
2006-10-13 |
2009-07-01 |
Medigene AG |
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
|
|
WO2008076257A2
(en)
|
2006-12-13 |
2008-06-26 |
Schering Corporation |
Treating cancer with anti-igflr antibody 19d12 = sch 717454
|
|
JP2010513278A
(ja)
|
2006-12-13 |
2010-04-30 |
シェーリング コーポレイション |
Ｉｇｆ１ｒインヒビターを用いた癌の処置方法
|
|
CA2673472A1
(en)
|
2006-12-21 |
2008-07-03 |
Vertex Pharmaceuticals Incorporated |
5-cyan0-4- (pyrrolo) [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
|
|
TW200836773A
(en)
|
2007-01-12 |
2008-09-16 |
Wyeth Corp |
Tablet-in-tablet compositions
|
|
MX338185B
(es)
|
2007-01-25 |
2016-04-05 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
|
EP2124901B1
(en)
|
2007-02-01 |
2017-07-19 |
Takeda Pharmaceutical Company Limited |
Tablet preparation without causing a tableting trouble
|
|
WO2008121467A2
(en)
|
2007-02-28 |
2008-10-09 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for treating cancer
|
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
|
US8715665B2
(en)
|
2007-04-13 |
2014-05-06 |
The General Hospital Corporation |
Methods for treating cancer resistant to ErbB therapeutics
|
|
JP2010525326A
(ja)
|
2007-04-19 |
2010-07-22 |
ウェルスタット バイオロジックス コーポレイション |
分離されていない循環癌細胞由来のＨｅｒ−２／ｎｅｕタンパク質の上昇したレベルの検出および治療
|
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
|
WO2009005673A1
(en)
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Anti-igf1r
|
|
HUE027443T2
(en)
|
2007-09-10 |
2016-10-28 |
Boston Biomedical Inc |
A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
|
|
CA2700665A1
(en)
|
2007-09-24 |
2009-04-02 |
Tragara Pharmaceuticals, Inc. |
Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
EP2212432A4
(en)
|
2007-10-22 |
2011-10-19 |
Schering Corp |
COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
|
|
AU2008325219A1
(en)
|
2007-11-05 |
2009-05-14 |
Puretech Ventures |
Methods, kits, and compositions for administering pharmaceutical compounds
|
|
JP2011505873A
(ja)
|
2007-12-18 |
2011-03-03 |
シェーリング コーポレイション |
抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
|
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
|
WO2009105234A2
(en)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
|
|
NZ617520A
(en)
|
2008-02-25 |
2015-05-29 |
Nestec Sa |
Drug selection for breast cancer therapy using antibody-based arrays
|
|
US20100081632A1
(en)
|
2008-03-06 |
2010-04-01 |
Odyssey Thera, Inc. |
High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
|
|
EP2259797A2
(en)
|
2008-03-25 |
2010-12-15 |
Schering Corporation |
Methods for treating or preventing colorectal cancer
|
|
WO2009121031A1
(en)
|
2008-03-27 |
2009-10-01 |
Vascular Biosciences, Inc. |
Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
|
|
WO2009146034A2
(en)
|
2008-03-31 |
2009-12-03 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
WO2009126662A1
(en)
|
2008-04-08 |
2009-10-15 |
Syndax Pharmaceuticals, Inc. |
Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
|
|
EP2271658B1
(en)
|
2008-04-18 |
2016-11-09 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
|
|
CN102164941B
(zh)
|
2008-04-18 |
2015-05-27 |
里亚塔医药公司 |
抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
|
|
WO2009146216A2
(en)
|
2008-04-18 |
2009-12-03 |
Reata Pharmaceuticals. Inc. |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
|
ES2703274T3
(es)
|
2008-04-18 |
2019-03-07 |
Reata Pharmaceuticals Inc |
Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
|
|
JP5564490B2
(ja)
|
2008-04-18 |
2014-07-30 |
リアタ ファーマシューティカルズ インコーポレイテッド |
抗炎症性ファルマコアを含む化合物および使用法
|
|
MX2010012064A
(es)
|
2008-05-05 |
2010-12-06 |
Schering Corp |
Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
|
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
|
EP2915532B1
(en)
|
2008-06-17 |
2016-10-19 |
Wyeth LLC |
Antineoplastic combinations containing hki-272 and vinorelbine
|
|
US8314137B2
(en)
|
2008-07-22 |
2012-11-20 |
Trustess Of Dartmouth College |
Monocyclic cyanoenones and methods of use thereof
|
|
ES2614912T3
(es)
|
2008-08-04 |
2017-06-02 |
Wyeth Llc |
Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina
|
|
WO2010030835A2
(en)
|
2008-09-11 |
2010-03-18 |
Wyeth Llc |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
|
EP3075864A1
(en)
|
2008-10-14 |
2016-10-05 |
Caris MPI, Inc. |
Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
|
|
WO2010048477A2
(en)
|
2008-10-24 |
2010-04-29 |
Wyeth Llc |
Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
|
|
KR20110086844A
(ko)
|
2008-11-07 |
2011-08-01 |
엔즌 파마슈티칼스, 인코포레이티드 |
Ｅｒｂｂ－３（ｈｅｒ３）－선택적 조합 요법
|
|
WO2010085845A1
(en)
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
|
MX2011008221A
(es)
|
2009-02-04 |
2011-08-17 |
Bipar Sciences Inc |
Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
|
|
WO2010098627A2
(ko)
|
2009-02-27 |
2010-09-02 |
한올바이오파마주식회사 |
약제학적 제제
|
|
NZ620000A
(en)
|
2009-03-11 |
2015-07-31 |
Auckland Uniservices Ltd |
Prodrug forms of kinase inhibitors and their use in cancer therapy
|
|
EP3000467B1
(en)
|
2009-04-06 |
2023-03-01 |
Wyeth LLC |
Treatment regimen utilizing neratinib for breast cancer
|
|
AR076053A1
(es)
|
2009-04-14 |
2011-05-18 |
Schering Corp |
Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Ｅｇｆｒ 억제제 및 질환 치료방법
|
|
CA2766067A1
(en)
|
2009-07-02 |
2011-01-06 |
Wyeth Llc |
3-cyanoquinoline tablet formulations and uses thereof
|
|
WO2011008053A2
(ko)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
|
WO2011008054A2
(ko)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
|
KR101211227B1
(ko)
|
2009-08-25 |
2012-12-11 |
한올바이오파마주식회사 |
메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
WO2011025267A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
KR101190953B1
(ko)
|
2009-08-25 |
2012-10-12 |
한올바이오파마주식회사 |
메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
CA2775155A1
(en)
|
2009-10-01 |
2011-04-07 |
Csl Limited |
Method of treatment of philadelphia chromosome positive leukemia
|
|
HUE046606T2
(hu)
|
2009-11-09 |
2020-03-30 |
Wyeth Llc |
Neratinib maleát tabletta formái
|
|
CN102724962B
(zh)
|
2009-11-09 |
2017-05-17 |
惠氏有限责任公司 |
包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途
|
|
RS56741B1
(sr)
|
2009-11-13 |
2018-03-30 |
Daiichi Sankyo Europe Gmbh |
Materijal i postupci za lečenje ili prevenciju bolesti povezanih sa her-3
|
|
EP2509592A1
(en)
|
2009-12-07 |
2012-10-17 |
Boehringer Ingelheim International GmbH |
Bibw 2992 for use in the treatment of triple negative breast cancer
|
|
CA2783743C
(en)
|
2009-12-11 |
2022-10-04 |
Wyeth Llc |
Phosphatidylinositol-3-kinase pathway biomarkers
|
|
CA2787048C
(en)
|
2010-01-13 |
2021-06-22 |
Wyeth Llc |
A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor
|